ReviewJournal of pharmacokinetics and pharmacodynamics2002
Multiple-pool cell lifespan model of hematologic effects of anticancer agents.
Review in Journal of pharmacokinetics and pharmacodynamics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- A framework for precision "dosing" of mental healthcare services: algorithm development and clinical pilot.International journal of mental health systems · 2023Article
- A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.Journal of pharmacokinetics and pharmacodynamics · 2023Review
- Pharmacokinetic-pharmacodynamic modelling of the hypoglycaemic effect of pulsatile administration of human insulin in rats.Scientific reports · 2020Article
- Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.British journal of clinical pharmacology · 2020Article
- Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- Pharmacodynamic models of age-structured cell populations.Journal of pharmacokinetics and pharmacodynamics · 2015Review
- Pharmacokinetics and toxicity of repeated oral etoposide is altered by morphine coadministration in rats.European journal of drug metabolism and pharmacokinetics · 2015Article
- Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.PloS one · 2014Article
- Lifespan based indirect response models.Journal of pharmacokinetics and pharmacodynamics · 2012Review
- Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.International journal of nanomedicine · 2012Article
- Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.The Journal of pharmacology and experimental therapeutics · 2010Article
- An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Pharmacodynamic model for chemotherapy-induced anemia in rats.Cancer chemotherapy and pharmacology · 2008Article
- Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.Journal of pharmacokinetics and pharmacodynamics · 2007Article
- Population cell life span models for effects of drugs following indirect mechanisms of action.Journal of pharmacokinetics and pharmacodynamics · 2005Article
- Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.Journal of clinical pharmacology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The leukopenic effects of anticancer agents are described using a semi-physiologic multiple-pool cell lifespan model. The time course of myelosuppression in relation to the drug concentration vs. time profile was characterized using a three pool indirect model. The proliferation and maturation stages of myeloid cells in the bone marrow and cell removal from the circulation were quantitated with a cell life-span concept. Drug effects were assumed to take place in the bone marrow based on irreversible linear or capacity-limited cytotoxicity. Mathematical derivations and computer simulations (Adapt II) were used to examine the properties of the model. Data from the literature were also analyzed. Cell response profiles after therapy typically exhibit a lag period, reduction to a nadir, and return to baseline. The predicted values of the time periods of granulopoiesis were 10-14 days for proliferation, and 1-6 days for maturation of progenitor cells in the bone marrow. The proposed irreversible mechanism of cell killing by anticancer drugs explains previously observed relationships between leukocyte nadir counts and exposure to the drug and/or duration of drug concentrations above some threshold level. The model was applied to literature data for paclitaxel and etoposide effects on leukocyte counts. The predicted value of KC50 for paclitaxel ranged from 0.004 to 0.2 microgram/mL and for etoposide 2 micrograms/mL. The present model accounts for drug-induced leukopenia using a physiologic cell production and loss model and irreversible cytotoxicity in a precursor pool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.